

Melioidosis - A Lethal Trap for the Unwary

Lasitha B Samarakoon*

Singapore General Hospital, Singapore

Article Information

Received date: Aug 31, 2015

Accepted date: Sep 01, 2015

Published date: Sep 09, 2015

*Corresponding author

Lasitha B Samarakoon, Singapore General Hospital, Singapore,

Tel: 0065 86610121;

Email(s): lasithabhagya.samarakoon@mohh.com.sg / lasithamfc@gmail.com

Distributed under Creative Commons CC-BY 4.0

Introduction

Melioidosis is an infection caused by the facultative intracellular gram-negative bacterium; *Burkholderia pseudomallei*, usually a soil saprophyte. It is a great masquerader of disease presenting in many disguises and mimics. Initially confined to Southeast Asia and Australia [1], it is now being recognized more and more, emerging as a infection with global impact [2]. We present a succinct review of literature on Melioidosis in view of raising the awareness of the reader with regards to this elusive infection.

Discussion

Melioidosis is an emerging infection, caused by *Burkholderia pseudomallei*. Commonly a soil saprophyte, it is endemic in South East Asia [2]. Melioidosis was the third commonest infective cause of death in Thailand after Human Immunodeficiency Virus (HIV) and Tuberculosis, in 2010 [3]. With increasing awareness about the organism, more and more case has been reported from areas outside the endemic area [4]. Single most important predisposing factor for developing Melioidosis is underlying Diabetes mellitus [5,6] with nearly half of cases infected having underlying diabetes [7].

Melioidosis is well known for its protean and varied manifestations. It can present with septicaemia [8] as well as localized forms such as septic arthritis [9,10] and psoas and gluteal abscess [11], necrotizing fascitis [12], making its presence felt in orthopedics. Although cases of mediastinal lymphadenopathy secondary to Melioidosis has been also reported [13,14], extensive search of the literature to date has revealed few reported cases of Melioidosis presenting as suppurative inguinal lymphadenopathy [14,15].

Bacterial culture from tissue samples remain the gold standard for diagnosing Melioidosis [16]. We wish to reiterate the importance of sending pus and tissue samples for routine microbiological analysis, in order not to miss the diagnosis [15]. Care must be taken when interpreting microbiological laboratory results though, as microbiologists unfamiliar with melioidosis may report the isolate as *Burkholderia pseudomallei* [15]. We wish to stress on the fact that if Melioidosis is suspected it should be specifically conveyed to the microbiologist, especially in settings where Melioidosis is not endemic. Serological titers, although not confirmatory, are also usual adjuncts to diagnose Melioidosis [17]. Commercial kits have been developed to aid rapid diagnosis of Melioidosis [18]. If histologically examined, Melioidosis may be noted to produce necrotizing inflammation with abscess formation or granulomata with multinucleated giant cells [19], mimicking Tuberculosis closely.

Mortality of Melioidosis remains substantial, significantly worse when associated with septicaemia [20]. Thus, early diagnosis and prompt treatment prior to the development of systemic sepsis is of importance in reducing the mortality associated with Melioidosis.

High index of suspicion is necessary for diagnosing Melioidosis. Having diagnosed successfully, effectively treating this uncommon condition is the next hurdle facing the clinician as *B. pseudomallei* is resistant to most commonly used antimicrobials such as third generation Cephalosporins, Quinolones and Aminoglycosides [21].

Ceftazidime is the drug of choice as it highly efficacious against *B. pseudomallei* [22], although prolonged regimens are necessary [23] to prevent the patient relapsing. Emerging resistance to Ceftazidime has been a concern, and thought to be circumvented by addition of Clavulinic acid to the therapeutic regimen [24].

What does the future hold with respect to treatment of this elusive condition? Recent reports suggest that Glyburide, a compound that has anti-inflammatory effects on the immune system, may be beneficial in Melioidosis [25]. Recently there has also been interest in surface protein induced vaccine against *Burkholderia pseudomallei* [26].

Conclusion

We believe that raising awareness among clinicians about this elusive entity can lead to prompt diagnosis and reduction of morbidity, minimizing the delay in diagnosis of this elusive condition.

References

1. White NJ. Melioidosis. *Lancet*. 2003; 361: 1715-1722.
2. Chaowagul W, White NJ, Dance DA, Wattanagoon Y, Naigowit P, Davis TM, et al. Melioidosis: A major cause of community-acquired septicemia in northeastern Thailand. *The Journal of infectious diseases*. 1989; 159: 890-899.
3. Limmathurotsakul D, Wongratanacheewin S, Teerawattanasook N, Wongsuvan G, Chaisuksant S, Chetchotisakd P, et al. Increasing incidence of human melioidosis in Northeast Thailand. *The American journal of tropical medicine and hygiene*. 2010; 82: 1113-1117.
4. Rolim DB, Vilar DC, Sousa AQ, Miralles IS, de Oliveira DC, Harnett G, et al. Melioidosis, northeastern Brazil. *Emerging infectious diseases*. 2005; 11: 1458-1460.
5. Cheng AC, Hanna JN, Norton R, Hills SL, Davis J, Krause VL, et al. Melioidosis in northern Australia, 2001-02. *Communicable diseases intelligence quarterly report*. 2003; 27: 272-277.
6. Draper AD, Mayo M, Harrington G, Karp D, Yinfoo D, Ward L, et al. Association of the melioidosis agent *Burkholderia pseudomallei* with water parameters in rural water supplies in Northern Australia. *Applied and environmental microbiology*. 2010; 76 :5305-5307.
7. Hassan MR, Pani SP, Peng NP, Voraru K, Vijayalakshmi N, Mehanderkar R, et al. Incidence, risk factors and clinical epidemiology of melioidosis: a complex socio-ecological emerging infectious disease in the Alor Setar region of Kedah, Malaysia. *BMC infectious diseases*. 2010; 10: 302.
8. Jesudason MV, Anbarasu A, John TJ: Septicaemic melioidosis in a tertiary care hospital in south India. *The Indian journal of medical research*. 2003; 117: 119-121.
9. Danda D, Thomas K. Transient aseptic arthritis of knees in a patient with melioidosis. *Indian journal of medical sciences*. 2000; 54: 18-20.
10. Caldera AS, Kumanan T, Corea E. A rare cause of septic arthritis: melioidosis. *Tropical doctor*. 2013; 43: 164-166.
11. Vidyalakshmi K, Shrikala B, Bharathi B, Suchitra U. Melioidosis: an under-diagnosed entity in western coastal India: a clinico-microbiological analysis. *Indian journal of medical microbiology*. 2007; 25: 245-248.
12. Wang YS, Wong CH, Kurup A. Cutaneous melioidosis and necrotizing fasciitis caused by *Burkholderia pseudomallei*. *Emerging infectious diseases*. 2003; 9: 1484-1485.
13. Saravu K, Mukhopadhyay C, Eshwara VK, Shastry BA, Ramamoorthy K, Krishna S, et al. Melioidosis presenting with mediastinal lymphadenopathy masquerading as malignancy: A case report. *Journal of medical case reports*. 2012; 6: 28.
14. Chlebicki MP, Tan BH. Six cases of suppurative lymphadenitis caused by *Burkholderia pseudomallei* infection. *Transactions of the Royal Society of Tropical Medicine and Hygiene*. 2006; 100: 798-801.
15. Wijekoon S, Prasath T, Corea EM, Elwigigala JP. Melioidosis presenting as lymphadenitis: A case report. *BMC research notes*. 2014; 7: 364.
16. Limmathurotsakul D, Peacock SJ. Melioidosis: A clinical overview. *British medical bulletin*. 2011; 99: 125-139.
17. Chantratita N, Wuthiekanun V, Thanwisai A, Limmathurotsakul D, Cheng AC, Chierakul W, et al. Accuracy of enzyme-linked immunosorbent assay using crude and purified antigens for serodiagnosis of melioidosis. *Clinical and vaccine immunology*. 2007; 14: 110-113.
18. Dance DA, Wuthiekanun V, Naigowit P, White NJ. Identification of *Pseudomonas pseudomallei* in clinical practice: Use of simple screening tests and API 2ONE. *Journal of clinical pathology*. 1989; 42: 645-648.
19. Wong KT, Puthucheary SD, Vadivelu J. The histopathology of human melioidosis. *Histopathology*. 1995; 26: 51-55.
20. How SH, Ng KH, Jamalludin AR, Shah A, Rathor Y. Melioidosis in Pahang, Malaysia. *The Medical journal of Malaysia*. 2005; 60: 606-613.
21. Kenny DJ, Russell P, Rogers D, Eley SM, Titball RW. In vitro susceptibilities of *Burkholderia mallei* in comparison to those of other pathogenic *Burkholderia* spp. *Antimicrobial agents and chemotherapy* 1999; 43: 2773-2775.
22. White NJ, Dance DA, Chaowagul W, Wattanagoon Y, Wuthiekanun V, Pitakwatchara N. Halving of mortality of severe melioidosis by ceftazidime. *Lancet*. 1989; 23: 697-701.
23. Sookpranee M, Boonma P, Susaengrat W, Bhuripanyo K, Punyagupta S. Multicenter prospective randomized trial comparing ceftazidime plus co-trimoxazole with chloramphenicol plus doxycycline and co-trimoxazole for treatment of severe melioidosis. *Antimicrobial agents and chemotherapy*. 1992; 36: 158-162.
24. Dance DA, Wuthiekanun V, Chaowagul W, White NJ. The antimicrobial susceptibility of *Pseudomonas pseudomallei*. Emergence of resistance in vitro and during treatment. *The Journal of antimicrobial chemotherapy*. 1989; 24: 295-309.
25. Koh GC, Maude RR, Schreiber MF, Limmathurotsakul D, Wiersinga WJ, Wuthiekanun V, et al. Glyburide is anti-inflammatory and associated with reduced mortality in melioidosis. *Clinical infectious diseases : An official publication of the Infectious Diseases Society of America*. 2011; 52: 717-725.
26. Hara Y, Mohamed R, Nathan S. Immunogenic *Burkholderia pseudomallei* outer membrane proteins as potential candidate vaccine targets. *PloS one*. 2009; 4: e6496.